Tellgen

Tellgen Debt / Assets

The Debt-to-Assets Ratio of Tellgen (300642.SZ) as of Oct 28, 2026 is 0.17. In the previous year, Debt-to-Assets Ratio was 0.06 — a change of 213.01% (higher).

Debt / Assets

0.17

YoY

213.01%

Last updated:

Debt-to-Assets Ratio of Tellgen is 2025 0.17 . Debt-to-Assets Ratio of Tellgen was 2024 0.06 . It decreases by 213.01% higher compared to the previous year.

The Tellgen Debt / Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt / Assets
Date
Debt / Assets
Jan 1, 2018
0.02 CNY
Jan 1, 2019
0.01 CNY
Jan 1, 2020
0.01 CNY
Jan 1, 2021
0.01 CNY
Jan 1, 2022
0.01 CNY
Jan 1, 2023
0.00 CNY
Jan 1, 2024
0.06 CNY
Jan 1, 2025
0.17 CNY
The Tellgen Debt / Assets history
YEARDebt / AssetsYoY
0.17+213.01%
0.06+1,449.12%
0.00-72.78%
0.01+16.81%
0.01-5.94%
0.01-14.71%
0.01-41.45%
0.02-46.82%
0.05-6.97%
0.05-37.70%
0.08—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tellgen Stock analysis

What does Tellgen do? Tellgen Corp develops, manufactures, and markets molecular diagnostic products including immunodiagnostic, molecular diagnostic, and biochemical diagnostic products. Their portfolio features tumor marker detection, HPV nucleic acid testing, autoimmune disease detection, and lung cancer methylation mutation detection products. The company targets healthcare providers and laboratories seeking advanced diagnostic solutions for disease detection and monitoring. Tellgen Corp generates revenue through the sale of these specialized diagnostic products to medical institutions and healthcare facilities. The firm's product lines focus on specific diagnostic needs such as cancer screening and infectious disease testing. Immunodiagnostic products detect antibodies and antigens, molecular diagnostic products analyze genetic material, and biochemical diagnostic products measure metabolic markers. Tellgen Corp sells these products directly to hospitals, clinics, and diagnostic laboratories across China and potentially internationally. Tellgen Corp's revenue streams come from the commercialization of its diagnostic product portfolio. The company's offerings address key healthcare challenges including early cancer detection and infectious disease management. Their products are designed to support clinical decision-making and patient care pathways in medical settings. Tellgen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tellgen stock

Debt-to-Assets Ratio of Tellgen is 0.17 in 2025.

Debt-to-Assets Ratio of Tellgen changed from 0.06 to 0.17, representing a 213.01% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt-to-Assets Ratio Tellgen since 2006 – with annual values, charts, and detailed analysis.

The Debt-to-Assets ratio measures what percentage of a company's assets are financed through debt. Higher ratios indicate greater financial risk.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt-to-Assets Ratio's Tellgen with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Tellgen

All Key Metrics — Tellgen